Education
About Us
Working with TipRanks
Follow Us
Matthew D'onofrio Insider Profile
4 Followers
Matthew D'onofrio, CEO, Director at Evoke Pharma, holds 0.00 shares in Evoke Pharma (Ticker: EVOK).
Matthew D'onofrio Evoke Pharma (EVOK)CEO, Director
Evoke Pharma (EVOK)
CEO, Director
Not Ranked
Matthew D'onofrio has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Matthew D'onofrio does not currently own shares as a corporate insider.
A breakdown of Matthew D'onofrio's holdings
Insider Roles
Matthew D'onofrio does not currently hold a role as a corporate insider.
Roles that Matthew D'onofrio holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Matthew D'onofrio
Matthew D'onofrio's Trading History
List of latest transactions for each holding click on a transaction to see Matthew D'onofrio's performance on stock
You May Also Like
Matthew D'onofrio insider profile FAQ
What is the percentage of profitable transactions made by Matthew D'onofrio?
The percentage of profitable transactions made by Matthew D'onofrio is ―.
What is the average return per transaction made by Matthew D'onofrio?
The average return per transaction made by Matthew D'onofrio is ―.
What stocks does Matthew D'onofrio hold?
Matthew D'onofrio holds: EVOK stocks.
What was Matthew D'onofrio’s latest transaction?
Matthew D'onofrio latest transaction was an Uninformative Sell of ―.
What was Matthew D'onofrio's most profitable transaction?
Matthew D'onofrio’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Matthew D'onofrio's role in Evoke Pharma?
Matthew D'onofrio's role in Evoke Pharma is CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.